Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cote

Showing results (101-110 of 213) with videos related to

Pageof 22
Sort By:
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Malaria Journal|July 6, 2021
Malaria prevalence and long-lasting insecticidal net use in rural western Uganda: results of a cross-sectional survey conducted in an area of highly variable malaria transmission intensityClaire M Cote, Varun Goel, Rabbison Muhindo, et al.
Cancer|July 10, 2024
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordomaGregory M Cote, Anthony P Conley, Steven Attia, et al.
Biochemistry|November 26, 2013
Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinityShaun M Cote, Thomas D Gilmore, Robert Shaffer, et al.
Journal of Cell Science|August 30, 2018
T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assemblyKrisna C Duong-Ly, Yin-Ming Kuo, Matthew C Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2018
Clinicopathologic characteristics of poorly differentiated chordomaAngela R Shih, Gregory M Cote, Ivan Chebib, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Journal of the American Chemical Society|March 20, 2013
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interfaceMary S Golden, Shaun M Cote, Marianna Sayeg, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Pageof 22

Showing results (101-110 of 213) with videos related to

Sort By:
Pageof 22
Advances in Therapy|May 8, 2021
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular AtrophyDoreen Barrett, Sanela Bilic, Yung Chyung, et al.
Malaria Journal|July 6, 2021
Malaria prevalence and long-lasting insecticidal net use in rural western Uganda: results of a cross-sectional survey conducted in an area of highly variable malaria transmission intensityClaire M Cote, Varun Goel, Rabbison Muhindo, et al.
Cancer|July 10, 2024
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordomaGregory M Cote, Anthony P Conley, Steven Attia, et al.
Biochemistry|November 26, 2013
Mutation of nonessential cysteines shows that the NF-κB essential modulator forms a constitutive noncovalent dimer that binds IκB kinase-β with high affinityShaun M Cote, Thomas D Gilmore, Robert Shaffer, et al.
Journal of Cell Science|August 30, 2018
T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assemblyKrisna C Duong-Ly, Yin-Ming Kuo, Matthew C Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2018
Clinicopathologic characteristics of poorly differentiated chordomaAngela R Shih, Gregory M Cote, Ivan Chebib, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Journal of the American Chemical Society|March 20, 2013
Comprehensive experimental and computational analysis of binding energy hot spots at the NF-κB essential modulator/IKKβ protein-protein interfaceMary S Golden, Shaun M Cote, Marianna Sayeg, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Pageof 22